A novel combination of oridonin and valproic acid in enhancement of apoptosis induction of HL-60 leukemia cells

  • Authors:
    • Meiyan Shi
    • Xia Ren
    • Xidi Wang
    • Hengxiao Wang
    • Guoqiang Liu
    • Xiaofen Yuan
    • Shubo Zheng
    • Linchang Yu
    • Sufei Pan
    • Guanhua Song
    • Qiang Guo
    • Lianlian Li
    • Xiaoyu Zhang
    • Zhiyong Zhang
    • Huifang Ding
    • Guosheng Jiang
  • View Affiliations

  • Published online on: December 15, 2015     https://doi.org/10.3892/ijo.2015.3294
  • Pages: 734-746
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Oridonin, obtained from the traditional Chinese herbal medicine rabdosia rubescens, exerts potent antitumor activities in cancer cells. Valproic acid (VPA), as a potent histone deacetylase inhibitor (HDACI), also plays an important role in inhibition of proliferation of tumor cells. However, there are no reports so far on the cooperation between oridonin and VPA for anti-leukemic effect. Therefore, in the present study, we undertook experiments to determine whether lower concentration of oridonin in conjunction with lower concentration of VPA would produce even more encouraging synergistic effect than each of them alone, and to clarify its molecular mechanism. The results demonstrated that the lower concentration of oridonin in combination with lower concentration of VPA synergistically inhibited the proliferation of HL-60 cells, and induced obvious caspase-dependent apoptosis through activation of the intrinsic apoptosis pathway, which is involved in the downregulation of Bcl-2/Bax ratio, release of cytochrome c to cytosol and caspase-9 activation, as well as through the extrinsic apoptosis pathway mediated by Fas/FasL and caspase-8 activation. In addition, MAPK signaling pathway was also involved in apoptosis induced by oridonin plus VPA. Furthermore, the combination treatment in vivo remarkably reduced the xenograft tumor size and triggered tumor cell apoptosis. Taken together, the novel combination of oridonin plus VPA exerted synergistic anti-proliferative and apoptosis-inducing effects on human myeloid leukemia cells, and may serve as a potential promising anti-leukemia strategy.

References

1 

Lengfelder E, Hofmann WK and Nolte F: Management of elderly patients with acute promyelocytic leukemia: Progress and problems. Ann Hematol. 92:1181–1188. 2013. View Article : Google Scholar : PubMed/NCBI

2 

Chen Z, Chen GQ, Shen ZX, Chen SJ and Wang ZY: Treatment of acute promyelocytic leukemia with arsenic compounds: In vitro and in vivo studies. Semin Hematol. 38:26–36. 2001. View Article : Google Scholar : PubMed/NCBI

3 

Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ and Wang ZY: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 72:567–572. 1988.PubMed/NCBI

4 

Zhang L and Zhu X: Epidemiology, diagnosis and treatment of acute promyelocytic leukemia in children: The experience in china. Mediterr J Hematol Infect Dis. 4:e20120122012. View Article : Google Scholar : PubMed/NCBI

5 

Tallman MS and Nabhan C: Management of acute promyelocytic leukemia. Curr Oncol Rep. 4:381–389. 2002. View Article : Google Scholar : PubMed/NCBI

6 

Douer D: Advances in the treatment of relapsed acute promyelocytic leukemia. Acta Haematol. 107:1–17. 2002. View Article : Google Scholar : PubMed/NCBI

7 

Tallman MS, Nabhan C, Feusner JH and Rowe JM: Acute promyelocytic leukemia: Evolving therapeutic strategies. Blood. 99:759–767. 2002. View Article : Google Scholar : PubMed/NCBI

8 

Sanz MA, Martín G and Lo Coco F: Choice of chemotherapy in induction, consolidation and maintenance in acute promyelocytic leukaemia. Best Pract Res Clin Haematol. 16:433–451. 2003. View Article : Google Scholar : PubMed/NCBI

9 

Nasr R, Lallemand-Breitenbach V, Zhu J, Guillemin MC and de Thé H: Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure. Clin Cancer Res. 15:6321–6326. 2009. View Article : Google Scholar : PubMed/NCBI

10 

Tomita A, Kiyoi H and Naoe T: Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in acute promyelocytic leukemia. Int J Hematol. 97:717–725. 2013. View Article : Google Scholar : PubMed/NCBI

11 

Hillestad LK: Acute promyelocytic leukemia. Acta Med Scand. 159:189–194. 1957. View Article : Google Scholar : PubMed/NCBI

12 

Liu JJ, Wu XY, Peng J, Pan XL and Lu HL: Antiproliferation effects of oridonin on HL-60 cells. Ann Hematol. 83:691–695. 2004. View Article : Google Scholar : PubMed/NCBI

13 

Gao F, Tang Q, Yang P, Fang Y, Li W and Wu Y: Apoptosis inducing and differentiation enhancement effect of oridonin on the all-trans-retinoic acid-sensitive and -resistant acute promyelocytic leukemia cells. Int J Lab Hematol. 32(1p1): e114–e122. 2010. View Article : Google Scholar

14 

Zhou GB, Kang H, Wang L, Gao L, Liu P, Xie J, Zhang FX, Weng XQ, Shen ZX, Chen J, et al: Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood. 109:3441–3450. 2007. View Article : Google Scholar : PubMed/NCBI

15 

Gao FH, Hu XH, Li W, Liu H, Zhang YJ, Guo ZY, Xu MH, Wang ST, Jiang B, Liu F, et al: Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc. BMC Cancer. 10:6102010. View Article : Google Scholar : PubMed/NCBI

16 

Chen G, Wang K, Yang BY, Tang B, Chen JX and Hua ZC: Synergistic antitumor activity of oridonin and arsenic trioxide on hepatocellular carcinoma cells. Int J Oncol. 40:139–147. 2012.

17 

Marks PA, Richon VM and Rifkind RA: Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst. 92:1210–1216. 2000. View Article : Google Scholar : PubMed/NCBI

18 

Konopleva M, Contractor R, Kurinna SM, Chen W, Andreeff M and Ruvolo PP: The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells. Leukemia. 19:1350–1354. 2005. View Article : Google Scholar : PubMed/NCBI

19 

Phiel CJ, Zhang F, Huang EY, Guenther mg, Lazar MA and Klein PS: Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 276:36734–36741. 2001. View Article : Google Scholar : PubMed/NCBI

20 

Cimino G, Lo-Coco F, Fenu S, Travaglini L, Finolezzi E, Mancini M, Nanni M, Careddu A, Fazi F, Padula F, et al: Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res. 66:8903–8911. 2006. View Article : Google Scholar : PubMed/NCBI

21 

Tang R, Faussat AM, Majdak P, Perrot JY, Chaoui D, Legrand O and Marie JP: Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Leukemia. 18:1246–1251. 2004. View Article : Google Scholar : PubMed/NCBI

22 

Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 58:621–681. 2006. View Article : Google Scholar : PubMed/NCBI

23 

Liu J, Bi G, Wen P, Yang W, Ren X, Tang T, Xie C, Dong W and Jiang G: Down-regulation of CD44 contributes to the differentiation of HL-60 cells induced by ATRA or HMBA. Cell Mol Immunol. 4:59–63. 2007.PubMed/NCBI

24 

Shimizu S, Narita M and Tsujimoto Y: Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature. 399:483–487. 1999. View Article : Google Scholar : PubMed/NCBI

25 

Constantinou C, Papas KA and Constantinou AI: Caspase-independent pathways of programmed cell death: The unraveling of new targets of cancer therapy? Curr Cancer Drug Targets. 9:717–728. 2009. View Article : Google Scholar : PubMed/NCBI

26 

Sun KW, Ma YY, Guan TP, Xia YJ, Shao CM, Chen LG, Ren YJ, Yao HB, Yang Q and He XJ: Oridonin induces apoptosis in gastric cancer through Apaf-1, cytochrome c and caspase-3 signaling pathway. World J Gastroenterol. 18:7166–7174. 2012. View Article : Google Scholar

27 

Bao R, Shu Y, Wu X, Weng H, Ding Q, Cao Y, Li M, Mu J, Wu W, Ding Q, et al: Oridonin induces apoptosis and cell cycle arrest of gallbladder cancer cells via the mitochondrial pathway. BMC Cancer. 14:2172014. View Article : Google Scholar : PubMed/NCBI

28 

Kawagoe R, Kawagoe H and Sano K: Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways. Leuk Res. 26:495–502. 2002. View Article : Google Scholar : PubMed/NCBI

29 

Ramos S: Cancer chemoprevention and chemotherapy: Dietary polyphenols and signalling pathways. Mol Nutr Food Res. 52:507–526. 2008. View Article : Google Scholar : PubMed/NCBI

30 

Zhang W and Liu HT: MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 12:9–18. 2002. View Article : Google Scholar : PubMed/NCBI

31 

Lunghi P, Tabilio A, Dall'Aglio PP, Ridolo E, Carlo-Stella C, Pelicci PG and Bonati A: Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts. Leukemia. 17:1783–1793. 2003. View Article : Google Scholar : PubMed/NCBI

32 

Wu J, Wong WW, Khosravi F, Minden MD and Penn LZ: Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res. 64:6461–6468. 2004. View Article : Google Scholar : PubMed/NCBI

33 

Jin S, Shen JN, Wang J, Huang G and Zhou JG: Oridonin induced apoptosis through Akt and MAPKs signaling pathways in human osteosarcoma cells. Cancer Biol Ther. 6:261–268. 2007. View Article : Google Scholar : PubMed/NCBI

34 

Wang H, Ye Y, Chui JH, Zhu GY, Li YW, Fong DW and Yu ZL: Oridonin induces G2/M cell cycle arrest and apoptosis through MAPK and p53 signaling pathways in HepG2 cells. Oncol Rep. 24:647–651. 2010.PubMed/NCBI

35 

McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 1773:1263–1284. 2007. View Article : Google Scholar

36 

Henson ES and Gibson SB: Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: Implications for cancer therapy. Cell Signal. 18:2089–2097. 2006. View Article : Google Scholar : PubMed/NCBI

37 

Bu HQ, Liu DL, Wei WT, Chen L, Huang H, Li Y and Cui JH: Oridonin induces apoptosis in SW1990 pancreatic cancer cells via p53- and caspase-dependent induction of p38 MAPK. Oncol Rep. 31:975–982. 2014.

38 

Chiu CC, Chen JY, Lin KL, Huang CJ, Lee JC, Chen BH, Chen WY, Lo YH, Chen YL, Tseng CH, et al: p38 MAPK and NF-kappaB pathways are involved in naphtho[1,2-b] furan-4,5-dione induced anti-proliferation and apoptosis of human hepatoma cells. Cancer Lett. 295:92–99. 2010. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

February 2016
Volume 48 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Shi, M., Ren, X., Wang, X., Wang, H., Liu, G., Yuan, X. ... Jiang, G. (2016). A novel combination of oridonin and valproic acid in enhancement of apoptosis induction of HL-60 leukemia cells. International Journal of Oncology, 48, 734-746. https://doi.org/10.3892/ijo.2015.3294
MLA
Shi, M., Ren, X., Wang, X., Wang, H., Liu, G., Yuan, X., Zheng, S., Yu, L., Pan, S., Song, G., Guo, Q., Li, L., Zhang, X., Zhang, Z., Ding, H., Jiang, G."A novel combination of oridonin and valproic acid in enhancement of apoptosis induction of HL-60 leukemia cells". International Journal of Oncology 48.2 (2016): 734-746.
Chicago
Shi, M., Ren, X., Wang, X., Wang, H., Liu, G., Yuan, X., Zheng, S., Yu, L., Pan, S., Song, G., Guo, Q., Li, L., Zhang, X., Zhang, Z., Ding, H., Jiang, G."A novel combination of oridonin and valproic acid in enhancement of apoptosis induction of HL-60 leukemia cells". International Journal of Oncology 48, no. 2 (2016): 734-746. https://doi.org/10.3892/ijo.2015.3294